New hope for aggressive brain tumors: experimental drug combo enters key trial

NCT ID NCT07297212

First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 18 times

Summary

This study tests an experimental drug called pumitamig, alone or with other medicines, in adults whose glioblastoma (a fast-growing brain cancer) has returned after standard treatment. The goal is to see if these treatments can shrink tumors and control the disease. About 75 participants will receive one of three treatment plans, and researchers will monitor safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Cancer Hospital of Shandong First Medical University

    RECRUITING

    Jinan, 250117, China

  • Affiliated Tumor Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, 350209, China

  • Beijing Tiantan Hospital, Capital Medical University

    RECRUITING

    Beijing, 100070, China

  • Huashan Hospital, Fudan University

    RECRUITING

    Shanghai, 201107, China

  • Shenzhen Second People's Hospital

    RECRUITING

    Shenzhen, 518000, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, 430030, China

Conditions

Explore the condition pages connected to this study.